TIDMCPT
RNS Number : 8073U
Concepta PLC
17 July 2018
17 July 2018
Concepta PLC
("Concepta" or the "Company")
Board Changes
Concepta PLC (AIM:CPT), the UK healthcare company and developer
of a proprietary product targeted at the mobile health market and
with a primary focus on women's fertility is pleased to announce
the following Board changes.
Matthew Walls has been appointed as Chairman of the Board with
immediate effect. Adam Reynolds, currently Chairman, will move to
the role of Non-Executive Director.
Matthew brings extensive senior and board-level experience in
public companies, particularly in pharmaceutical, diagnostics and
biotech businesses. Matthew was most recently Chief Executive
Officer and Chairman of the leading international patient
behavioural change company, Atlantis Healthcare Group from 2015
until 2018.
Matthew has held Chairman and advisory roles since 2013 for The
Fertility Partnership, which has grown to become the UK's largest
fertility group; Matthew was previously Non-Executive Director and
Chairman of Artificial Intelligence start-up, BioBeats Group
Limited from 2016 until 2018; and Chief Executive Officer of
AIM-listed molecular diagnostics company Genedrive Plc between 2007
and 2015, where he led the admission of the Company to AIM with the
Company attaining 'Technology Company of the Year' in 2009 and
2015.
Matthew has also held the role of Chief Executive Officer at
Oxford Biosignals Limited, Internexus Group Limited and Supanet
Limited, and Zylepsis Limited between the years of 2000 and 2006
and was previously Global Commercial Director at the
biopharmaceutical company AstraZeneca Plc where he was commercially
and financially responsible for strategy and international business
operations.
The Board also announces that Peter Dines has been appointed as
Non-Executive Director with immediate effect. Peter currently holds
the role of Chief Operating Officer & Head of Life Sciences and
Biosciences at Mercia Technologies, Concepta's major shareholder.
Peter has over two decades' experience in the healthcare sector
having founded and run a number of successful healthcare technology
businesses. Notable successes during his career include his time at
orthopaedic and obstetrics equipment firm Surgicraft, and founder
of spinal implant company Surgi C, a company that saw sales
quadruple under his leadership. Finally, Dr Mark Wyatt has stepped
down from his role as Non-Executive Director with immediate effect
to focus on his other business interests.
Commenting on the Board changes, Erik Henau, Chief Executive
Officer, said:
"We are thrilled to welcome Matthew Walls, who brings with him a
wealth of experience in developing and leading both international
pharma and healthcare groups, and SME companies. His fantastic
track record in achieving commercial success and knowledge of
corporate governance, regulatory issues, and delivery of strategic
plans in the healthcare arena will be instrumental to Concepta as
it enters this important phase in its expansion.
"Further, we are delighted to welcome Peter Dines as a
Non-Executive Director. With over 20 years' experience in managing
growth businesses in the healthcare and pharma sector, Peter will
be a welcome addition to the Board and will further strengthen our
team as we continue to scale the business.
"On behalf of the Board, I would like to thank Adam Reynolds for
being instrumental to Concepta's AIM listing in 2016 and the
contribution he has made in his role as Chairman since then. We are
delighted that he will remain on the Board as Non-Executive
Director. We would also like to thank Dr Mark Wyatt for his
valuable service to the Board of Directors and we wish him every
success in his future roles."
AIM Rules Disclosures
Save for the information above and below, there are no further
disclosures to be made in accordance with Rule 17, Schedule 2(g) of
the AIM Rules for Companies in respect of the appointment of
Matthew Walls
Full name: Matthew Heaton Walls
Age: 54 years old
Matthew Walls is, or has during the last five years, been, a
director of the following companies:
Past 5 years
Atlantis Healthcare Group Limited
BioBeats Group Limited
Reprogenetics UK Limited
Genedrive Plc
Epistem Plc
Save for the information above and below, there are no further
disclosures to be made in accordance with Rule 17, Schedule 2(g) of
the AIM Rules for Companies in respect of the appointment of Peter
Dines
Full name: Peter Michael Dines
Age: 45 years old
Peter Dines is, or has during the last five years, been, a
director of the following companies:
Current Past 5 years
Mercia Fund Management Limited Digital Life Sciences Limited
Mercia Growth Nominees Limited Digital Life Sciences Group
Limited
Mercia Growth Nominees 3 Limited CISIV Limited
Mercia Growth Nominees 4 Limited Bishop Veseys Grammar School
Mercia Growth Nominees 8 Limited Foodient Limited
Mercia Digital Nominees Limited
Mercia Growth Nominees 7 Limited
University Growth Fund Nominees
Limited
The Clive and Sylvia Richards
Charity
Mercia Fund Management (Nominees)
Limited
WM AHSN SME General Partner
Limited
Diagnostic World Limited
C7 Ventures Limited
Mr Dines was appointed company director of Digital Life Sciences
Limited, a provider of digital technology and consultancy solutions
to the NHS, which is currently undergoing a creditors' voluntary
liquidation with a preferential creditors' shortfall of GBP34,488.
A voluntary liquidator was appointed on 24th Jan 2017 and the
liquidators' statement was posted March 2018. Mr Dines was the
largest creditor to the business due to loans provided by the
parent company. There were no criticisms/findings against Mr Dines
in relation to this case
-ENDS-
Enquiries:
The Company
Erik Henau
CEO
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
NOVUM Securities Limited (Broker)
Colin Rowbury
Tel: +44 (0) 20 7399 9400
Yellow Jersey (Financial PR)
Georgia Colkin / Joe Burgess / Katie Bairsto
Tel: +44 (0) 776 932 5254
Notes to Editors
Concepta PLC
Concepta PLC is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus, targeted at the
personalised mobile health market with a primary focus on
unexplained infertility in women.
myLotus is currently the only consumer product which allows both
quantitative and qualitative home test measurement of a woman's
personal luteinizing hormone (LH) during ovulation and human
chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus is to help women
conceive naturally.
Concepta has made significant progress recently, establishing
relationships with a number of distributors in China where myLotus
has been given cFDA approval. Concepta is initially targeting the
traditional route to market in China through Chinese hospitals and
plans to add the direct-to-consumer route in the near future.
The Company is also well on its way to achieving CE-marking and
commencing its direct-to-consumer launch in the UK and Europe in H2
2018. The Company has identified a significant global market
opportunity, with revenue potential of the Chinese and EU
unexplained infertility market estimated to be worth c.GBP600m per
annum.
Unexplained infertility refers to women that have been unable to
conceive after 6 months of trying. This highly motivated target
group of consumers won't typically be offered medical intervention
until 12 months of unsuccessfully trying, with IVF not offered
until two years. Research indicates couples start to take positive
action ahead of this time and there is little medical support to
help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOADQLFFVDFXBBQ
(END) Dow Jones Newswires
July 17, 2018 02:00 ET (06:00 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024